Lonza Expands Service Platform to Viral Vaccines, Gene Therapy Vectors

Lonza (Basel, Switzerland) has entered the viral basedmanufacturing market with its purchase of Vivante GMP Solutions, Inc. (Houston, TX). The acquisition advances Lonza's strategy to broaden its biologies custom service offering for the growing viral vaccine and gene therapy markets.

Vivante is a custom manufacturing organization dedicated to producing GMP viral-based therapeutics. The company's viral-vaccine production services will be enhanced by Lonza's expertise in expression technologies and large-scale manufacturing platforms. Additionally, Vivante's experience with preclinical through late-stage supply of viral …